Deciphering the emergence of mutations in Pseudomonas aeruginosa after ceftolozane/tazobactam treatment and evaluating therapeutic alternatives

Abstract Objectives Ceftolozane/tazobactam is a relevant option for treating multiresistant Pseudomonas aeruginosa, a major public health problem. Over a 14-month period, we studied the frequency of ceftolozane/tazobactam resistance development and mechanisms underlying resistance in P. aeruginosa i...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Léa Bientz, Hugo Boijout, Raoudha Grami, Ulysse Guyet, Marin Lahouati, Melissande Hertzmann, Antony Marques, Audrey Toirot, Sabine Aillerie, Laure Coulange-Mayonnove, Alexis Groppi, Macha Nikolski, Cécile Bébéar, Véronique Dubois
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2025-12-01
Rangatū:	BMC Microbiology
Ngā marau:	Pseudomonas aeruginosa Multidrug resistance Ceftolozane/tazobactam Cephalosporinase New antibiotics
Urunga tuihono:	https://doi.org/10.1186/s12866-025-04517-z
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!